Where can I find news about CALA?

The latest headlines, third-party analysis, and SEC filings for Calithera Biosciences, Inc. (CALA) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are CALA's SEC filings?

Calithera Biosciences, Inc. (CALA)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are CALA's earnings call transcripts?

Full earnings call transcripts for Calithera Biosciences, Inc. (CALA) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

CALA

Calithera Biosciences, Inc.

OTC·Biotechnology · Healthcare

$0.00$0.00+0.00%

Market cap$487.00·Market closed·Aug 26 8:00 PM UTC

News & Analysis

Vistance Networks Reports Second Quarter 2026 Results
Vistance Networks, Inc. (NASDAQ: VISN), a global leading provider of intelligent network solutions, today reported results for the quarter ended June 30, 2026.*
gurufocus.comAug 6, 2026 · 8:00 AM
Calithera Biosciences (NASDAQ:CALA) Shares Pass Above Fifty Day Moving Average – What’s Next?
Calithera Biosciences, Inc. (NASDAQ: CALA - Get Free Report)'s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.00 and traded as high as $0.0001. Calithera Biosciences shares last traded at $0.0001, with a volume of 887 shares changing hands. Calithera Biosciences
defenseworld.netMar 31, 2026 · 3:13 AM
Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast
Institutional and Insider Ownership 0.1% of Merck KGaA shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Earnings and Valuation This table compares Calithera Biosciences and
defenseworld.netMar 9, 2026 · 2:23 AM
Calithera Biosciences (NASDAQ:CALA) Stock Passes Above Fifty Day Moving Average – Time to Sell?
Calithera Biosciences, Inc. (NASDAQ: CALA - Get Free Report)'s stock price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.00 and traded as high as $0.0002. Calithera Biosciences shares last traded at $0.0002, with a volume of 235 shares trading hands. Calithera Biosciences
defenseworld.netJan 10, 2026 · 3:52 AM
Marriott International Announces Changes to its Continent Leadership and a Strategic Realignment Across Key Regions
Unified structure for U.S., Canada & CALA under Satya Anand's leadership; Neal Jones to lead EMEA; Federico "Fede" Greppi to head CALA; retirements of Marriott veterans Liam Brown and Brian King announced. BETHESDA, Md.
prnewswire.comJan 9, 2026 · 8:45 AM
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and thank you for standing by.
seekingalpha.comNov 14, 2022 · 10:17 PM
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
globenewswire.comNov 8, 2022 · 4:30 PM
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial.
marketwatch.comOct 3, 2022 · 9:08 AM

SEC Filings

No recent filings indexed.

Frequently Asked Questions About CALA

Where can I find news about CALA?: The latest headlines, third-party analysis, and SEC filings for Calithera Biosciences, Inc. (CALA) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are CALA's SEC filings?: Calithera Biosciences, Inc. (CALA)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are CALA's earnings call transcripts?: Full earnings call transcripts for Calithera Biosciences, Inc. (CALA) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Calithera Biosciences, Inc.

Frequently Asked Questions About CALA

Calithera Biosciences, Inc.

Vistance Networks Reports Second Quarter 2026 Results

Calithera Biosciences (NASDAQ:CALA) Shares Pass Above Fifty Day Moving Average – What’s Next?

Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast

Calithera Biosciences (NASDAQ:CALA) Stock Passes Above Fifty Day Moving Average – Time to Sell?

Marriott International Announces Changes to its Continent Leadership and a Strategic Realignment Across Key Regions